Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1 Moditope vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab with or without Ipilimumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC).

Trial Details

NCT ID
NCT05329532
Phase
PHASE1 / PHASE2
Sponsor
Scancell Ltd
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • Modi-1 Moditope
  • Pembrolizumab
  • MicronJet600™ microneedle device (NanoPass)
Locations (sample)
  • Brighton, Default, United Kingdom|50.82838,-0.13947
  • Cardiff, Default, United Kingdom|51.48,-3.18
  • Edinburgh, Default, United Kingdom|55.95206,-3.19648
  • Guildford, Default, United Kingdom|51.23536,-0.57427
  • London, Default, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Patient either has one of the following histologically or cytologically confirmed advanced cancers not amenable to curative intent surgical resection:
  • SCCHN (oral cavity, oropharynx, hypopharynx, or larynx)
  • HGSOC including fallopian tube and primary peritoneal cancers
  • RCC Or the patient has histologically or cytologically confirmed SCCHN scheduled to have curative intent surgical resection.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →